Aviva’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $111M | Buy |
223,593
+1,141
| +0.5% | +$506K | 0.16% | 110 |
|
|
2026
Q1 | $99.3M | Buy |
222,452
+6,241
| +3% | +$2.91M | 0.17% | 116 |
|
|
2025
Q4 | $98M | Buy |
216,211
+11,322
| +6% | +$4.88M | 0.17% | 119 |
|
|
2025
Q3 | $80.2M | Buy |
204,889
+12,229
| +6% | +$5.11M | 0.15% | 136 |
|
|
2025
Q2 | $85.8M | Buy |
192,660
+11,970
| +7% | +$5.52M | 0.18% | 119 |
|
|
2025
Q1 | $87.6M | Buy |
180,690
+25,200
| +16% | +$11.7M | 0.21% | 105 |
|
|
2024
Q4 | $62.6M | Buy |
155,490
+30,650
| +25% | +$14.2M | 0.16% | 127 |
|
|
2024
Q3 | $58.1M | Buy |
124,840
+2,923
| +2% | +$1.4M | 0.15% | 157 |
|
|
2024
Q2 | $57.1M | Buy |
121,917
+23,916
| +24% | +$10.4M | 0.16% | 130 |
|
|
2024
Q1 | $41M | Sell |
98,001
-28,982
| -23% | -$12.3M | 0.13% | 180 |
|
|
2023
Q4 | $51.7M | Buy |
126,983
+17,357
| +16% | +$6.41M | 0.19% | 107 |
|
|
2023
Q3 | $38.1M | Buy |
109,626
+8,816
| +9% | +$3.08M | 0.16% | 119 |
|
|
2023
Q2 | $35.5M | Sell |
100,810
-55,572
| -36% | -$18.7M | 0.14% | 153 |
|
|
2023
Q1 | $49.3M | Buy |
156,382
+4,121
| +3% | +$1.24M | 0.22% | 96 |
|
|
2022
Q4 | $44M | Sell |
152,261
-18,744
| -11% | -$5.71M | 0.22% | 103 |
|
|
2022
Q3 | $49.5M | Sell |
171,005
-23,816
| -12% | -$6.85M | 0.29% | 61 |
|
|
2022
Q2 | $54.9M | Buy |
194,821
+47,073
| +32% | +$12.6M | 0.29% | 62 |
|
|
2022
Q1 | $38.6M | Buy |
147,748
+54,224
| +58% | +$12.9M | 0.19% | 102 |
|
|
2021
Q4 | $20.5M | Sell |
93,524
-8,617
| -8% | -$1.68M | 0.09% | 221 |
|
|
2021
Q3 | $18.5M | Buy |
102,141
+6,025
| +6% | +$1.18M | 0.08% | 243 |
|
|
2021
Q2 | $19.4M | Buy |
96,116
+9,156
| +11% | +$1.92M | 0.09% | 238 |
|
|
2021
Q1 | $18.7M | Sell |
86,960
-416
| -0.5% | -$91.4K | 0.09% | 209 |
|
|
2020
Q4 | $20.6M | Buy |
87,376
+3,535
| +4% | +$811K | 0.11% | 192 |
|
|
2020
Q3 | $22.8M | Sell |
83,841
-2,712
| -3% | -$748K | 0.13% | 135 |
|
|
2020
Q2 | $25.1M | Sell |
86,553
-4,520
| -5% | -$1.23M | 0.16% | 121 |
|
|
2020
Q1 | $21.7M | Buy |
91,073
+984
| +1% | +$226K | 0.16% | 117 |
|
|
2019
Q4 | $19.7M | Sell |
90,089
-504
| -0.6% | -$102K | 0.12% | 155 |
|
|
2019
Q3 | $15.3M | Sell |
90,593
-3,548
| -4% | -$628K | 0.1% | 181 |
|
|
2019
Q2 | $17.3M | Sell |
94,141
-2,340
| -2% | -$409K | 0.12% | 168 |
|
|
2019
Q1 | $17.7M | Buy |
96,481
+175
| +0.2% | +$32.3K | 0.12% | 173 |
|
|
2018
Q4 | $16M | Sell |
96,306
-26,489
| -22% | -$4.59M | 0.12% | 182 |
|
|
2018
Q3 | $23.7M | Sell |
122,795
-4,353
| -3% | -$775K | 0.13% | 168 |
|
|
2018
Q2 | $21.6M | Sell |
127,148
-835
| -0.7% | -$129K | 0.13% | 173 |
|
|
2018
Q1 | $20.9M | Sell |
127,983
-12,550
| -9% | -$2.05M | 0.13% | 174 |
|
|
2017
Q4 | $21.1M | Sell |
140,533
-17,545
| -11% | -$2.6M | 0.12% | 193 |
|
|
2017
Q3 | $24M | Buy |
158,078
+3,420
| +2% | +$515K | 0.13% | 183 |
|
|
2017
Q2 | $19.9M | Buy |
154,658
+1,980
| +1% | +$238K | 0.11% | 212 |
|
|
2017
Q1 | $16.7M | Sell |
152,678
-8,487
| -5% | -$747K | 0.1% | 233 |
|
|
2016
Q4 | $11.9M | Buy |
161,165
+10,610
| +7% | +$863K | 0.07% | 294 |
|
|
2016
Q3 | $13.1M | Buy |
150,555
+3,286
| +2% | +$311K | 0.08% | 280 |
|
|
2016
Q2 | $12.7M | Buy |
147,269
+11,649
| +9% | +$1.01M | 0.09% | 264 |
|
|
2016
Q1 | $10.8M | Buy |
135,620
+1,456
| +1% | +$132K | 0.08% | 274 |
|
|
2015
Q4 | $16.9M | Sell |
134,164
-797
| -0.6% | -$96.2K | 0.13% | 171 |
|
|
2015
Q3 | $14.1M | Sell |
134,961
-1,808
| -1% | -$232K | 0.12% | 205 |
|
|
2015
Q2 | $16.9M | Buy |
136,769
+8,100
| +6% | +$1.02M | 0.12% | 196 |
|
|
2015
Q1 | $15.2M | Buy |
128,669
+32,001
| +33% | +$3.83M | 0.1% | 224 |
|
|
2014
Q4 | $11.5M | Sell |
96,668
-210
| -0.2% | -$23.7K | 0.09% | 256 |
|
|
2014
Q3 | $10.9M | Sell |
96,878
-80
| -0.1% | -$7.62K | 0.09% | 256 |
|
|
2014
Q2 | $9.18M | Buy |
96,958
+200
| +0.2% | +$14K | 0.07% | 315 |
|
|
2014
Q1 | $6.84M | Buy |
96,758
+4,810
| +5% | +$381K | 0.06% | 369 |
|
|
2013
Q4 | $6.83M | Buy |
91,948
+8,344
| +10% | +$581K | 0.06% | 360 |
|
|
2013
Q3 | $6.34M | Sell |
83,604
-254,788
| -75% | -$20.3M | 0.06% | 354 |
|
|
2013
Q2 | $27M | Buy |
+338,392
| New | +$24.9M | 0.27% | 92 |
|
Other funds holding VRTX
Aviva's VRTX Position: Q2 2026 in Review
Aviva increased its Vertex Pharmaceuticals (VRTX) stake by 0.51% in Q2 2026, buying an estimated $506K and bringing the position to 223,593 shares worth $111M. The position accounts for 0.16% of the portfolio, ranked #110.
Aviva first reported a position in VRTX in Q2 2013 and has held it in 53 quarters since. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.
- Aviva held 223,593 shares of Vertex Pharmaceuticals worth $111M as of Q2 2026.
- Aviva bought 1,141 Vertex Pharmaceuticals shares in Q2 2026, an estimated $506K.
- Vertex Pharmaceuticals made up 0.16% of Aviva's portfolio in Q2 2026, its #110 holding.
- Aviva first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 53 quarters since.
- 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.
Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.